AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01644370
Drug: HAART
RxNorm normalized name: porcine heart preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: as per Thai HIV Treatment guidelines
Trial: NCT01141179
Drug: LEO 27847
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2 mL (0.1 mg) dose of oral solution
Trial: NCT04063527
Drug: adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: combination of paclitaxel and carboplatin
Trial: NCT02261025
Drug: acetylsalicylic acid
RxNorm normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 75-100mg,per day
Trial: NCT03989037
Drug: SIBP-01
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IBP-01: injection; strength: 150mg; first dose 8mg/kg (intravenous infusion, not less than 90 minutes, on the 1st day of each cycle), then 6mg/kg once every 3 weeks, totaling 6 cycles
Trial: NCT03669367
Drug: hydroxycloroquina
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral hydroxycloroquina 5 mg/Kg/day for 2 years (0-48 months)
Trial: NCT01689740
Drug: Full Dose MDMA-assisted therapy (125 mg)
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Initial dose of 125 mg midomafetamine HCl administered orally at the start of each of two psychotherapy sessions, possibly followed by a supplemental dose of 62.5 mg 1.5 to 2.5 hours later.
Trial: NCT01689740
Drug: Open-Label Full Dose MDMA-assisted therapy (125 mg)
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Initial dose of 125 mg midomafetamine HCl administered orally at the start of each of two psychotherapy sessions, possibly followed by a supplemental dose of 62.5 mg 1.5 to 2.5 hours later.
Trial: NCT02956005
Drug: ENVARSUS®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ENVARSUS XR is a form of the anti-rejection drug, tacrolimus, for people who have had a kidney transplant
Trial: NCT01440257
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules once daily
Trial: NCT01440257
Drug: CCX140-B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CCX140-B capsules once daily (Group B)
Trial: NCT01115582
Drug: Cholic acid
RxNorm normalized name: Cholic Acid
DrugBank: Cholic Acid (DB02659)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: The IUPAC name for cholic acid is 3 alpha,7alpha,12 alpha-trihydroxy-5 beta-cholanoic acid. The international nonproprietary name (INN) is cholic acid.~Each patient will be given a box containing a 1 month supply of study drug. Each bottle will contain 90 capsules; each capsule will contain either 50 or 250 mg of manufactured cholic acid depending upon the child's weight. The study drug will be taken orally, in divided doses (as determined by the investigator), for a total daily dose of 10-15 mg/kg body weight. Parents of infants and young children who are unable to swallow the TBM cholic acid capsule will be instructed to sprinkle the contents of the capsule over 1-2 teaspoons of plain applesauce and feed it to the child.
Trial: NCT04562766
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400mg Caplet
Trial: NCT02942576
Drug: VKA-Based Regimen
RxNorm normalized name: Anacin Aspirin Regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dosed at International Normalised Ratio (INR) levels, which is a test of how long it takes for blood to clot. Standard of Care treatment in Canada, Italy, Poland, Hungary, Czech Republic, United Kingdom (UK), Taiwan and Korea.
Trial: NCT02942576
Drug: VKA-Based Regimen
RxNorm normalized name: Anacin Aspirin Regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dosed at INR levels. Standard of Care treatment in Germany, Belgium, and the Netherlands.
Trial: NCT02942576
Drug: VKA-Based Regimen
RxNorm normalized name: Anacin Aspirin Regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dosed at INR levels. Standard of Care treatment in France.
Trial: NCT02942576
Drug: VKA-Based Regimen
RxNorm normalized name: Anacin Aspirin Regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dosed at INR levels. Standard of Care treatment in Spain.
Trial: NCT04508621
Drug: Placebo SL Tablet
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will take 1 tablet of randomly assigned study drug sublingually starting on Day 1 for 2 weeks. At the Week 2 visit, all patient will have the dose increased to 2 tablets for 12 weeks.
Trial: NCT00057785
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1000 mg/m\^2/day as 96-hour continuous infusion on days 71-74, 99-102, and 127-130
Trial: NCT02336698
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered once every 4 weeks for 16 weeks by subcutaneous (SC) injection (injection under the skin) into the thigh or abdomen.
Trial: NCT01725737
Drug: GlyTI-M
RxNorm normalized name: m-phenylenediamine
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01725737
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Comparator: starch
Trial: NCT00377715
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03137758
Drug: PCUR - 101
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PCUR-101 Capsules 25 mg are solid dosage forms for oral administration
Trial: NCT02432456
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individuals enrolled into the control arm of the trial will receive a normal saline placebo infusion at a rate equivalent to the dosage of ketamine in the experimental arm.
Trial: NCT02432456
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All patients admitted to the hospital will be placed on scheduled acetaminophen 1000mg PO q 6 hours unless signs of liver disease/impairment or creatinine clearance \< 35ml/min at which point dosage would be reduced to 650mg q 8 hours. Individuals unable to take oral medications would be placed on intravenous acetaminophen.
Trial: NCT02432456
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: All patients will be placed on scheduled Ibuprofen or an equivalent NSAID at dosage of 600mg every 6 hours. Patients must have a Glomerular Filtration Rate \> 60 ml/min with no contraindications to NSAID therapy (e.g. Aspirin use, allergy/sensitivity, concurrent ACE inhibitor use, other nephrotoxins, etc)
Trial: NCT02432456
Drug: Opioid
RxNorm normalized name: OPIOIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All individuals will receive as needed opiate therapy as an adjunct to the scheduled medications and ketamine/placebo solution. Choice in opiate therapy will be at the discretion of the attending trauma faculty. Dosage and adjustments will be in accordance with the institutional policy on appropriate opiate dosage adjustment.
Trial: NCT01552629
Drug: QGE031
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01552629
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00763971
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsule once per day (Overencapsulated)
Trial: NCT03809455
Drug: Fentanyl citrate
RxNorm normalized name: Fentanyl Citrate
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fentanyl citrate arm (FAR Arm): one intake of fentanyl citrate 100 µg (intranasal or buccal).~Placebo Arm: one intake of placebo (intranasal or buccal) The administration route will be left to the discretion of the investigator taking into account the patient's profile (capable of maintaining the sublingual tablet without swallowing, absence of nasal discharge...), and/or the patient's choice.~Medication Commercial name Formulation Administration route Dose Fentanyl citrate Pecfent® Nasal spray Intranasal 100 µg Fentanyl citrate Abstral® Sublingual tablet Buccal 100 µg For the cohort the choice of treatment by FAR is at the centres discretion, according to standard of practice.~Treatment duration: 1 day
Trial: NCT03809455
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: one intake of placebo (intranasal or buccal)
Trial: NCT00388505
Drug: Tobramycin Inhalation Powder
RxNorm normalized name: Tobramycin Inhalation Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tobramycin Inhalation Powder (TIP) capsules for inhalation.
Trial: NCT00388505
Drug: Tobramycin Solution for Inhalation
RxNorm normalized name: tobramycin Inhalation Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tobramycin solution for inhalation (TOBI), supplied as 300 mg/5mL ampoules administered with a nebulizer
Trial: NCT02173301
Drug: XP23829 400 mg QD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: active dose 1
Trial: NCT02173301
Drug: XP23829 400 mg BID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: active dose 3
Trial: NCT02173301
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: control
Trial: NCT00430638
Drug: olmesartan medoxomil + hydrochlorothiazide, if necessary
FDA approved: no
EMA approved: no
PMDA approved: no
Description: olmesartan medoxomil + hydrochlorothiazide, if necessary. Oral tablets administered for once daily for 12 weeks
Trial: NCT00430638
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablets administered for once daily for 12 weeks
Trial: NCT01083758
Drug: LEO 80185 (Taclonex® Scalp topical suspension/Xamiol® gel)
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical suspension applied once daily for up to 8 weeks
Trial: NCT00618436
Drug: Phenytoin
RxNorm normalized name: Phenytoin
DrugBank: Phenytoin (DB00252)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The group will receive a loading dose of fosphenytoin 20 mg/kg IV to a maximum of 2000 mg, then started on maintenance dose of 5mg/kg/day, rounded to nearest 100mg dose, IV, q 12h for seven days.
Trial: NCT00719550
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered at 625mg/m2 BID orally every day while on study.
Trial: NCT01017575
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets, Oral, 0 mg, daily, 48 weeks
Trial: NCT01007253
Drug: PL nasal spray
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2 puffs of PL nasal spray (from GlaxoSmithKline) in each nostril once a day for 1 week
Trial: NCT01007253
Drug: PL eye drops
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 drop of placebo eye drops (lubricant eye drops with active ingredients 0.3% glycerin) in each eye once a day for 1 week
Trial: NCT02517099
Drug: Beclometasone
RxNorm normalized name: Beclometasone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beclometasone dipropionate 200mcg bd for 4 months
Trial: NCT02517099
Drug: Co-amoxiclav
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Co-amoxiclav 0.3ml/kg bd for 4 weeks
Trial: NCT02048293
Drug: Remifentanyl, Ultiva®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anesthetic induction for orotracheal intubation. Group O
Trial: NCT02048293
Drug: Remifentanil Laboratorios Chalver de Colombia S.A.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anesthetic induction for orotracheal intubation. Group A
Trial: NCT02048293
Drug: Fada Remifentanilo
RxNorm normalized name: Remifentanilo
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Anesthetic induction for orotracheal intubation. Group B
Trial: NCT02793128
Drug: UGN-101 instillations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment with UGN-101 once weekly for a total of 6 times; in a retrograde fashion. Patients who will demonstrate complete response (CR) will be treated with UGN-101 once monthly as a maintenance therapy for a total of 11 instillations or up to the first recurrence whichever comes first.
Trial: NCT02517099
Drug: Azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Azithromycin 10mg/kg od for 4 weeks
Trial: NCT00062036
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT06537778
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants in the placebo group received only normal saline infusion for the same duration as atosiban group.
Trial: NCT01529749
Drug: EFV/FTC/TDF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600/200/245 mg, od, oral
Trial: NCT01529749
Drug: FTC/TDF + MK-0518
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FTC/TDF --\> 200/245 mg, oral MK-0518 --\> 400 mg, oral
Trial: NCT03995628
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One dose of placebo on post-operative day 3 after tonsillectomy
Trial: NCT04515576
Drug: LY3493269
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC
Trial: NCT04515576
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC
Trial: NCT01074047
Drug: Conventional Care Regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physician pre-selects prior to randomization from one of the following:~* Intensive chemotherapy (cytarabine 100-200 mg/m\^2 continuous intravenous infusion for 7 days + anthracycline IV x 3 days) + Best Supportive Care; induction with up to 2 consolidation cycles~* Low-dose cytarabine 20 mg subcutaneous (SC) twice a day (BID) for 10 days, for 28 day cycles + BSC; until disease progression or unacceptable toxicity~* Best Supportive Care only; until study end
Trial: NCT01876810
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One lactose pill twice a day for two weeks.
Trial: NCT02461030
Drug: In-office Villevie® prophy paste + Colgate Toothpaste
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylaxis with rubber cup using In-office Villevie® (fluoride-free) prophy paste + Colgate Toothpaste, after non-surgical periodontal therapy.
Trial: NCT04637620
Drug: Placebo Cap
RxNorm normalized name: PLACEBO CAP/TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Use of placebo as a comparator
Trial: NCT02182245
Drug: BIBF 1120
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01480284
Drug: GSK548470 300 mg tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blue tablets, each tablet containing 300 mg of tenofovir disoproxil fumarate
Trial: NCT01480284
Drug: ETV 0.5 mg capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brown capsules, each capsule containing 0.53 mg of entecavir hydrate
Trial: NCT01681134
Drug: Advagraf®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT01681134
Drug: Prograf®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT04439071
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablets
Trial: NCT03555448
Drug: Twice daily immunosuppression regimen
RxNorm normalized name: Anacin Aspirin Regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This is the arm which we are designating the standard, which will be the comparison to the active drug arm.
Trial: NCT04036448
Drug: REVLIMID®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: REVLIMID®
Trial: NCT00623974
Drug: Calcium
RxNorm normalized name: Calcium
DrugBank: Calcium sulfate (DB15533)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 milligrams by mouth (PO) Every 12 Hours
Trial: NCT01647750
Drug: Levothyroxine
RxNorm normalized name: Levothyroxine
DrugBank: Levothyroxine (DB00451)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Participants in the lower dose arm of the study will receive a lower dose of levothyroxine than their usual dose
Trial: NCT01647750
Drug: Levothyroxine
RxNorm normalized name: Levothyroxine
DrugBank: Levothyroxine (DB00451)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Participants in the standard dose of treatment will receive their usual dose of levothyroxine
Trial: NCT01389024
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sucrose solution 0.2 ml/kg/day by mouth once a day with blinded dose escalation of 0.05 ml/kg/day to match the frequency of dose escalation in the hydroxyurea arm.
Trial: NCT03302299
Drug: Pyridoxine 25 Mg Oral Tablet
RxNorm normalized name: pyridoxine 25 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All participants will also receive 25 mg pyridoxine (vitamin B-6) daily by mouth for 6 months for the treatment duration to reduce the risk of INH-induced peripheral neuropathy.
Trial: NCT00850837
Drug: HEC gel
RxNorm normalized name: ALCOHOL 73 L in 100 L TOPICAL GEL [Grand Valley Reagents HEC Hand Sanitizer Gel]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 g application of hydroxyethylcellulose gel
Trial: NCT02827123
Drug: Macintosh Laryngoscopy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orotracheal intubation with Macintosh Laryngoscopy after anesthetic induction
Trial: NCT01679366
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 tablet 2 times daily
Trial: NCT01679366
Drug: Probiotics
RxNorm normalized name: probiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 tablet twice daily
Trial: NCT03250975
Drug: Budesonide and Azithromycin
RxNorm normalized name: formoterol and budesonide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participant with acute laryngeal injury will be randomized at discharge to either a non-drug placebo control group or a medical therapy group consisting of azithromycin 250 mg and budesonide 0.5 mg for 14 days.
Trial: NCT01245595
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal Saline
Trial: NCT01494662
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 750 mg/m2 orally, twice daily (1,500 mg/m2 daily) for 14 days followed by 7 days off
Trial: NCT02787369
Drug: ACY-1215
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00504907
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00049452
Drug: zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT01817855
Drug: AZD7624
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple ascending doses (starting from 300 µg lung deposited dose up to 1200 µg) inhaled IMP via a nebulizer
Trial: NCT01817855
Drug: Placebo to match
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple doses inhaled placebo via a nebulizer
Trial: NCT02657356
Drug: Placebo capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02610153
Drug: Vitamin K Antagonist
RxNorm normalized name: Vitamin K antagonists
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The vitamin K antagonists exert their anticoagulant effect through inhibition of the enzyme complex of vitamin K epoxide reductase subunit 1 with subsequent reduction of the gamma-carboxylation of certain glutamic acid molecules endpoints located on factors coagulation II (prothrombin), VII, IX and X and protein C or its cofactor protein S. This gamma-carboxylation has a significant bearing on the interaction of coagulation factors referenced with calcium ions. Without this reaction, blood clotting cannot be initiated. The dose must be adjusted to each patient at baseline and after regular basis, since the sensitivity to anticoagulants varies between individuals and can also vary throughout the treatment. For this, the Prothrombin Time (PT) is used and standardized ratio called International Normalised Ratio (INR).
Trial: NCT05079789
Drug: Amiloride
RxNorm normalized name: Amiloride
DrugBank: Amiloride (DB00594)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Treatment with amiloride, start dose 5 mg
Trial: NCT00782795
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00807963
Drug: rHuPH20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: recombinant human hyaluronidase PH20 injection
Trial: NCT00807963
Drug: zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: subcutaneous injection
Trial: NCT00335894
Drug: hMG-IBSA
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00068588
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given orally
Trial: NCT03415126
Drug: ASN007 RD
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral drug for the treatment of advanced solid tumors
Trial: NCT03829241
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matched to troriluzole
Trial: NCT00698204
Drug: celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subject was asked to take celecoxib each day that radiation therapy was given.
Trial: NCT00698204
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subject was asked to take placebo each day that radiation therapy was given.
Trial: NCT02209454
Drug: Enantyum® oral solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One dose of 25 mg DKP oral solution
Trial: NCT01945554
Drug: Mephamesone
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01945554
Drug: Kenacort®
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01292447
Drug: Placebo gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inert gel x 1
Trial: NCT04480424
Drug: Standard Medical Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SMT per local policies or guidelines.